Search company, investor...
Darwin Biosciences company logo

Darwin Biosciences


Biz Plan Competition | Alive

Total Raised


Last Raised

$30K | 3 yrs ago

About Darwin Biosciences

Darwin Biosciences specializes in saliva-based diagnostic tests for infectious disease. The company is developing diagnostics that can identify people who are asymptomatic or pre-symptomatic for common infectious diseases, including COVID-19.

Headquarters Location

Boulder, Colorado,

United States

Missing: Darwin Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Darwin Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Darwin Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Darwin Biosciences is included in 3 Expert Collections, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

2,535 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Medical Devices

8,562 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Latest Darwin Biosciences News

Darwin Biosciences licenses rapid, noninvasive, on-site COVID-19 surveillance technology from the University of Colorado Boulder

Aug 18, 2020

The company’s CoVLab portable lab service delivers same-day results to reveal whether an asymptomatic individual is infected with the virus that causes COVID-19 | Source: Darwin Biosciences BOULDER, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Darwin Biosciences , a molecular diagnostics company improving the way the world manages infectious disease, today announced an exclusive license to technology that will facilitate commercialization of Darwin's point-of-need testing service. CoVLab is an end-to-end screening solution to detect pathogens associated with COVID-19 in individuals, including those who are asymptomatic or presymptomatic. The agreement includes technology associated with Darwin’s future products, beginning with SickStick. “Understanding the body’s early immune response to infection is vitally important because, as we all know with the novel coronavirus, by the time you’re showing symptoms, it’s too late — you’ve likely already spread the disease to other people,” said Nicholas Meyerson, CEO of Darwin Biosciences and a scientist in the department of Molecular, Cellular and Developmental Biology (MCDB) at CU Boulder. “CoVLab offers the fastest turnaround time available by eliminating the need for off-site or third-party labs. We offer comfortable, fast, affordable and accurate screenings to help people confidently return to work, school or other activities.”  All of the technology licensed by Darwin Biosciences was developed in the laboratory of Dr. Sara Sawyer, a professor in the MCDB department at CU Boulder and co-founder of Darwin Biosciences. CoVLab’s portable lab eliminates the delays associated with complex laboratory tests by providing all of the equipment necessary to: Collect saliva samples from individuals. Inactivate those samples (eliminating the need for a biosafety cabinet). Analyze samples for the presence of a SARS-CoV-2 genome using an isothermal amplification reaction with a colorimetric readout. CoVLab Benefits: Saliva-Based — CoVLab testing is noninvasive and highly tolerable when compared to the viral tests that obtain samples, for example, by way of a nasopharyngeal swab. Point of Need — CoVLab provides a scalable portable lab service to easily collect and inactivate self-collected saliva samples without the need for complex laboratory equipment. Rapid, Same-Day Results — CoVLab’s quick and simple screening service assists in reducing the spread of COVID-19 by informing individuals before they exhibit symptoms. “We’re just scratching the surface of how our technology will aid in infectious disease management,” said Rick Whitcomb, COO of Darwin Biosciences. “Our goal is to help slow the local transmission of disease during the current pandemic and to continue to transform the way infectious disease is managed in the future with our follow-on products.” For more information about Darwin Biosciences or CoVLab, please visit . About Darwin Biosciences  Darwin Biosciences is improving the way the world manages infectious disease. Through the development of CoVLab, Darwin Biosciences offers an end-to-end screening solution to detect pathogens associated with COVID-19 in asymptomatic or presymptomatic individuals. The portable lab service enables rapid collection and analysis of saliva in a highly tolerable, noninvasive and cost-effective manner. CoVLab’s saliva-based screenings, developed at the University of Colorado Boulder, are conducted at the point of need and deliver rapid, same-day results — typically in less than two hours — potentially stemming the spread of disease and allowing people to congregate with confidence. Darwin Biosciences is based in Boulder, Colorado. For more information about Darwin Biosciences or CoVLab, please visit . Melissa ChristensenMAPRagencymchristensen@mapr.agency970-363-4652

Darwin Biosciences Frequently Asked Questions (FAQ)

  • Where is Darwin Biosciences's headquarters?

    Darwin Biosciences's headquarters is located at Boulder.

  • What is Darwin Biosciences's latest funding round?

    Darwin Biosciences's latest funding round is Biz Plan Competition.

  • How much did Darwin Biosciences raise?

    Darwin Biosciences raised a total of $30K.

  • Who are the investors of Darwin Biosciences?

    Investors of Darwin Biosciences include University of Chicago New Venture Challenge.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.